Notably, butyrate has been shown to independently suppress breast cancer cell growth and, when combined with anti-HER2 monoclonal antibodies such as trastuzumab, synergistically enhances therapeutic efficacy (Garmpis et al., 2017; Chen et al., 2011). This evidence concerns the gene ERBB2 and breast carcinoma.